Literature DB >> 2138542

Clinical efficacy of teicoplanin.

P Calain1, F Waldvogel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2138542     DOI： 10.1007/bf01963637

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  14 in total

1.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

2.  Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.

Authors:  N Galanakis; H Giamarellou; N Vlachogiannis; C Dendrinos; G K Daikos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

3.  Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.

Authors:  Y Van Laethem; P Hermans; S De Wit; H Goosens; N Clumeck
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

4.  Evaluation of teicoplanin and vancomycin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

5.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.

Authors:  P Lewis; J J Garaud; F Parenti
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

7.  Teicoplanin.

Authors:  A H Williams; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1984-11       Impact factor: 5.790

8.  Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.

Authors:  C Leport; C Perronne; P Massip; P Canton; P Leclercq; E Bernard; P Lutun; J J Garaud; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

9.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

10.  Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.

Authors:  Y Glupczynski; H Lagast; P Van der Auwera; J P Thys; F Crokaert; E Yourassowsky; F Meunier-Carpentier; J Klastersky; J P Kains; E Serruys-Schoutens
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191
View more
  9 in total

1.  Treatment failure with teicoplanin and response to oral antibiotic regimens.

Authors:  P H McWhinney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.

Authors:  G S Perdikaris; A Pefanis; H Giamarellou; A Nikolopoulos; E P Margaris; I Donta; A Tsitsika; P Karayiannakos
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.

Authors:  C Y Liu; W S Lee; C P Fung; N C Cheng; C L Liu; S P Yang; S L Chen
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 4.  The value of new antimicrobial agents.

Authors:  J H Wagenvoort
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

5.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

6.  Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.

Authors:  H J Schaad; C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

7.  Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

8.  Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.

Authors:  A Kureishi; P J Jewesson; M Rubinger; C D Cole; D E Reece; G L Phillips; J A Smith; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 9.  Teicoplanin in perspective. A critical comparison with vancomycin.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1991-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.